id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-P-0123-0003,FDA,FDA-2005-P-0123,Letter from FDA CDER to ECR Pharmaceuticals,Other,LET-Letter,2006-01-03T05:00:00Z,2006,1,,,2024-12-13T20:03:12Z,,0,0,090000648043fc23
FDA-2005-P-0123-0002,FDA,FDA-2005-P-0123,Background Material: Federal Register re Letter from FDA CDER ECR Pharmaceuticals,Other,Background Material,2006-01-03T05:00:00Z,2006,1,,,2024-12-13T20:14:27Z,,0,0,090000648043fc22
FDA-2005-P-0123-0001,FDA,FDA-2005-P-0123,"Determination That DECADRON (Dexam@thasone) Tablets, 1.5 Milligrams,
Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,N-Notice,2005-12-29T05:00:00Z,2005,12,2005-12-27T05:00:00Z,,2024-12-13T19:52:31Z,,0,0,090000648043fc0c